Perrigo takes license for Clarinex patents, preps for launch of generic

ALLEGAN, Mich. Perrigo on Thursday announced that all Hatch-Waxman litigation relating to Schering-Plough’s prescription allergy medicine Clarinex (5 mg) has been settled with Perrigo taking a license under all relevant patents.

Under the terms of the settlement, Perrigo can commercially launch its generic desloratadine product on July 1, 2012, or earlier in certain circumstances. The new product launch may be a prescription or over-the-counter product, depending on its status at the time of launch. The Perrigo product is awaiting FDA approval.

Sales for Clarinex were approximately $300 million, according to Wolters Kluwer data for the twelve months ended Oct. 31, provided by Perrigo.